Microglial subtypes in neurodegeneration — friend vs foe
PARTIALLY ADDRESSED
Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protective phenotypes.
Landscape Summary:
Microglial subtypes in neurodegeneration — friend vs foe is a 0.75 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Microglial subtypes in neurodegeneration — friend vs foe — INVOKE-2 (completed)
📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%
Hypothesis Score Distribution
🏆 Competing Hypotheses (Ranked by Score)
No hypotheses linked to this gap yet.
🌊 Knowledge Graph Connections
No knowledge graph edges recorded
🕑 Activity Feed
✏update on knowledge_gapby None2026-04-25T22:15
💬 Discussion
No discussions yet. Be the first to comment.
📋 Investigation Sub-Tasks
Create sub-tasks to investigate specific aspects of this gap:
Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions